Qiagen Receives CE Mark for Therascreen EGFR Liquid Biopsy Test | GenomeWeb

NEW YORK(GenomeWeb) – Qiagen today announced that it has received a CE-IVD mark for its therascreen EGFR RGQ Plasma PCR kit, a liquid biopsy companion diagnostic to guide treatment for patients with non-small cell lung cancer.

The test, co-developed by Qiagen and AstraZeneca, is intended to help physicians identify which advanced NSCLC patients are more likely to benefit from treatment with AstraZeneca's EGFR inhibitor Iressa (gefitinib) in cases where when a suitable tumor tissue sample is not available.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.